iPSC-Derived NK Cell Therapies Gain Momentum with Regulatory Approvals and Expanding Clinical Pipeline

iPSC-derived natural killer (NK) cell therapies are advancing rapidly across clinical trials and regulatory pathways, with 12 or more companies now actively developing more than 15 pipeline drugs in the space. In a landmark regulatory milestone, Japan's Pharmaceuticals and Medical Devices Agency (PMDA) approved an iPS cell-derived NK cell therapy for mediastinal germ cell tumors in December 2025, leveraging CiRA's stem cell technology for regenerative treatment. The approval represents one of the first regulatory greenlights for an iPSC-derived NK cell product in a solid tumor indication.

Induced pluripotent stem cell (iPSC)-derived NK cells are immune effector cells generated by differentiating reprogrammed human somatic cells into NK cells under controlled laboratory conditions. These cells retain the innate cytotoxic properties of NK cells, including the ability to recognize and kill virus-infected or malignant cells without prior antigen sensitization. iPSC-derived NK cells offer key advantages over donor-derived NK cells, such as a renewable, standardized, and scalable "off-the-shelf" source with consistent phenotype and function. They can also be genetically engineered at the iPSC stage to enhance tumor targeting, persistence, or resistance to immunosuppressive tumor microenvironments.

Key companies developing iPSC-derived NK cell therapies include Century Therapeutics (NASDAQ: IPSC), Cartherics Pty Ltd, Fate Therapeutics (NASDAQ: FATE), Nuwacell Biotechnologies Co., Ltd., HebeCell, and Healios (TYO: 4593). Promising pipeline therapies in various stages of clinical trials include CNTY-101, CTH-401, FT522, NCR300, HC101a, and AKT-01. Approximately three or more iPSC-derived NK cell drugs are currently in the early stages of development.

In November 2025, Century Therapeutics announced that CNTY-101 clinical development activities will continue in CARAMEL, a Phase I/II investigator-sponsored trial. As of November 12, 2025, three B-cell-mediated autoimmune disease patients were treated in this trial. Initial clinical data from CARAMEL is expected to be presented by the trial investigators at the 14th Annual BMT & Cell Therapy Workshop in December 2025. As part of the company's clinical development re-prioritization efforts, Century is discontinuing its company-sponsored CALiPSO-1 trial, in which five patients have been treated with a favorable safety profile, no dose-limiting toxicities, no cytokine release syndrome above grade 2, and no immune effector cell-associated neurotoxicity syndrome. The limited but emerging clinical data from CALiPSO-1 suggest encouraging clinical activity in refractory patient populations.

In October 2025, ViGenCell signed a joint development agreement with Therabest for TB-420, an iPSC-derived NK cell therapy candidate. The broader pipeline momentum is being driven by the advantages iPSC-derived NK cells offer over primary NK cells, including clonal uniformity, inexhaustible supply, off-the-shelf manufacturability, and genetic engineering flexibility. As clinical validation advances and manufacturing and regulatory frameworks mature, iPSC-derived NK cells are expected to evolve from a promising innovation into a standardized and broadly accessible modality in cancer immunotherapy.

The iPSC-derived NK cell therapy space is part of a wider wave of cell-based immunotherapy advances in oncology. In the germ cell tumor treatment space specifically, Japan's health ministry fast-tracked reimbursement for PD-1 inhibitors in advanced germ cell tumors under the regenerative medicine act in October 2025, boosting immunotherapy access. These developments collectively signal growing momentum for iPSC-derived NK cell therapies as the next frontier in off-the-shelf cancer immunotherapy.